What are the available brands of insulin aspart (Novolog) in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Available Brands of Insulin Aspart in India

Based on the available evidence, there is no specific information about insulin aspart brands available in India in the provided references.

While the evidence provides comprehensive information about insulin aspart's pharmacological properties, clinical use, and pricing in the United States, none of the references specifically address the Indian market for insulin aspart products.

General Information About Insulin Aspart

  • Insulin aspart (NovoRapid, NovoLog) is a short-acting insulin analogue with faster onset and shorter duration of action than regular human insulin 1
  • It is designed to better mimic the endogenous insulin profile when administered just before meals 2
  • Insulin aspart is available in both vial and prefilled pen formulations according to U.S. pricing data 3

Insulin Aspart Formulations

  • Standard insulin aspart (U-100) is available in vials and prefilled pens 3
  • A "faster-acting" formulation of insulin aspart (Fiasp®) is also available, which contains additional excipients (L-arginine and niacinamide) to accelerate initial absorption 4
  • Biphasic insulin aspart (premixed formulations) is available in different ratios (30/70,50/50,70/30) combining rapid-acting insulin aspart with an intermediate-acting component 5

Clinical Considerations

  • Insulin aspart can be used in basal-bolus regimens with longer-acting insulins like insulin detemir 6
  • It provides better postprandial glycemic control than regular human insulin when administered immediately before meals 1
  • For patients requiring large insulin doses, concentrated insulin formulations may be more comfortable to inject 7

Limitations of Available Evidence

  • The provided references contain U.S. pricing data and clinical information but no specific data on Indian market availability 3
  • While one study mentioned use of insulin aspart in Indian patients with type 2 diabetes, it did not specify brand names available in India 6

Common Pitfalls

  • Maximum insulin dose in standard pen devices is typically 60-80 units per injection 7
  • For patients requiring larger doses, either multiple injections or concentrated insulin formulations should be considered 7
  • Proper insulin pen technique is essential for accurate dosing 7

Without specific information about insulin aspart brands in India, patients and healthcare providers should consult local pharmaceutical resources or the Indian drug regulatory authority for accurate and current information about available insulin aspart products in the Indian market.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.